References in periodicals archive ?
A 2013 study of brain-dead organ donors did find a 40% increased pancreatic mass in diabetes patients treated with incretin therapy, compared to those who didn't get it and to controls.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is commonly used in the treatment of type II diabetes mellitus (DM) for its effect on the incretin system (1).
Incretin mimetics are long-acting analogs of the gastric hormones called incretins, such as glucagon-like peptide-1 (GLP-1), which stimulate insulin release.
a) inhibiting the activity of the DPP-IV enzyme to prolong the effects of incretin
The most important incretin in glucose regulation is the glucagon-like peptide (GLP-1).
Medications that Restore Incretin Action (DPP-4 Inhibitors)
Already, a weekly incretin injection is close to Food & Drug Administration approval.
Glucose-dependent insulinotropic peptide (GIP) was the first and glucagon-like peptide 1 (GLP-1) the second, and final, incretin to be characterised.
Specially structure and function deterioration almost in 50% of [beta]-cell mass is observed in type 2 diabetes mellitus, but also incretin metabolism is abnormal because there is an evident decrease on incretin effect [5, 6], that is the reason of the reduction in nutrient-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) [7], this effect leads to an inappropriately elevated glucagon concentrations that results in hyperglycemia [3, 4].
Exenatide is the first and only approved incretin mimetic, a class of drugs for
Pseudin could join a new class of medicines called incretin mimetics which mimic natural substances.